Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officer
Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.
Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global Scientific Affairs at Bausch + Lomb, overseeing the medical and clinical development of the company’s surgical portfolio.
Explore More Articles
Is presbyopia the newest specialty?
The presbyopia landscape is crowded today with innovations to treat this condition, including corneal procedures, pharmacologic treatments, scleral procedures, and phakic and intraocular (IOL) lenses, according to Karolinne Maia Rocha, MD, PhD, director of cornea and refractive surgery at the Medical University of South Carolina in Charleston. Corneal proceduresProcedures that are coming down the pike …
read moreUnlocking the recovery of dynamic range of focus with microporation therapeutics
Laser Scleral Microporation (LSM) is a therapy which represents the first biomechanical solution to the biomechanical problems of progressive presbyopia. The therapy is performed using the VisioLite® Ophthalmic Laser system developed by Ace Vision Group (AVG). Today, having no biomechanical option able to meet the loss of dynamic range of focus (DRoF) that occurs with progressive …
read moreAce Vision Group Adds Four Ophthalmologists to Medical Advisory Board; Launches New Corporate and Medical Affairs Websites
Ace Vision Group announced the addition of Cathleen McCabe, MD; James Katz, MD; Ehsan Sadri, MD; and Dagny Zhu, MD, to its medical advisory board. These prominent ophthalmologists will contribute expertise to advance the development and implementation of novel solutions for eye health, specifically Laser Scleral Microporation (LSM), a laser therapeutic designed to rejuvenate the …
read more